Victory Capital Management
CTIC

Victory Capital Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Victory Capital Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13,294
Closed -$55.8K – 2663
2023
Q1 		$55.8K Sell
13,294
-243
-2% -$1.26K ﹤0.01% 2433
2022
Q4 		$81.4K Buy
13,537
+1,849
+16% +$10.1K ﹤0.01% 2390
2022
Q3 		$68K Sell
11,688
-2,549
-18% -$15.9K ﹤0.01% 2528
2022
Q2 		$85K Buy
14,237
+1,518
+12% +$7.77K ﹤0.01% 2482
2022
Q1 		$65K Sell
12,719
-363
-3% -$1.08K ﹤0.01% 2572
2021
Q4 		$32K Buy
13,082
+205
+2% +$502 ﹤0.01% 2664
2021
Q3 		$38K Sell
12,877
-646
-5% -$1.76K ﹤0.01% 2704
2021
Q2 		$34K Buy
13,523
+2,366
+21% +$5.67K ﹤0.01% 2685
2021
Q1 		$32K Buy
11,157
+37
+0.3% +$121 ﹤0.01% 2700
2020
Q4 		$36K Buy
11,120
+573
+5% +$1.91K ﹤0.01% 2477
2020
Q3 		$23K Sell
10,547
-603
-5% -$770 ﹤0.01% 2432
2020
Q2 		$13K Sell
11,150
-896
-7% -$946 ﹤0.01% 2463
2020
Q1 		$11K Buy
+12,046
New +$13.8K ﹤0.01% 3067
2019
Q4 		– Sell
-9,800
Closed -$8K – 3790
2019
Q3 		$8K Buy
+9,800
New +$7.48K ﹤0.01% 3359

Other funds holding CTIC

UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Victory Capital Management's CTIC Position: Q2 2023 in Review

Victory Capital Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 13,294 shares — an estimated $55.8K sold.

Victory Capital Management first reported a position in CTIC in Q3 2019 and held it in 14 quarters. The position peaked at $85K in Q2 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

  • Victory Capital Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
  • Victory Capital Management sold 13,294 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $55.8K.
  • Victory Capital Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2019 and held it in 14 quarters.
  • Victory Capital Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $85K in Q2 2022.
  • 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Victory Capital Management's 13F filing for Q2 2023, filed 27 Jul 2023.